 Heres a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks Biotech stocks hitting 52-week highs on Oct. 15 Celgene Corporation NASDAQ: CELG Eagle Pharmaceuticals Inc NASDAQ: EGRX Kodiak Sciences Inc NASDAQ: KOD The Medicines Company NASDAQ: MDCO Natera Inc NASDAQ: NTRA Ra Pharmaceuticals Inc NASDAQ: RARX Reata Pharmaceuticals Inc NASDAQ: RETA announced positive results for a Phase 2 study of its drug to treat Friedreich ataxia Relmada Therapeutics Inc NASDAQ: RLMD announced positive Phase 2 results for drug to treat treatment-resistant depression Zoetis Inc NYSE: ZTS Down In The Dumps Biotech stocks hitting 52-week lows on Oct. 15 Auris Medical Holding Ltd NASDAQ: EARS BENITEC BIOPHARS ADR NASDAQ: BNTC Chimerix Inc NASDAQ: CMRX Cleveland BioLabs, Inc. NASDAQ: CBLI Fulcrum Therapeutics Inc NASDAQ: FULC Heat Biologics Inc NASDAQ: HTBX INmune Bio Inc NASDAQ: INMB Kaleido Biosciences Inc NASDAQ: KLDO Karuna Therapeutics Inc NASDAQ: KRTX Mirum Pharmaceuticals Inc NASDAQ: MIRM Novus Therapeutics Inc NASDAQ: NVUS Orgenesis Inc NASDAQ: ORGS Phio Pharmaceuticals Corp NASDAQ: PHIO Precision BioSciences Inc NASDAQ: DTIL Pulmatrix Inc NASDAQ: PULM Sierra Oncology Inc NASDAQ: SRRA Strongbridge Biopharma plc NASDAQ: SBBP Stocks In Focus Akebia Sues CMS For Restoring Coverage For Kidney-Disease Related Anemia Drug Akebia Therapeutics Inc NASDAQ: AKBA has filed a compliant in federal district court against the Centers of Medicare Medicaid Service and the U.S. 